Virpax Pharmaceuticals Competitors

Universe Pharmaceuticals (NYSE:UPC) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Earnings and Valuation

This table compares Universe Pharmaceuticals and Virpax Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Universe Pharmaceuticals and Virpax Pharmaceuticals, as reported by MarketBeat.com.

Profitability

This table compares Universe Pharmaceuticals and Virpax Pharmaceuticals' net margins, return on equity and return on assets.

Viridian Therapeutics (NASDAQ:VRDN) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Viridian Therapeutics and Virpax Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Viridian Therapeutics and Virpax Pharmaceuticals, as provided by MarketBeat.com.

Viridian Therapeutics currently has a consensus price target of $34.00, suggesting a potential upside of 94.62%. Given Viridian Therapeutics' higher possible upside, equities research analysts clearly believe Viridian Therapeutics is more favorable than Virpax Pharmaceuticals.

Earnings & Valuation

This table compares Viridian Therapeutics and Virpax Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Summary

Viridian Therapeutics beats Virpax Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Virpax Pharmaceuticals (NASDAQ:VRPX) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings.

Profitability

This table compares Virpax Pharmaceuticals and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Virpax Pharmaceuticals and Inhibikase Therapeutics, as reported by MarketBeat.com.

Earnings & Valuation

This table compares Virpax Pharmaceuticals and Inhibikase Therapeutics' revenue, earnings per share (EPS) and valuation.

Summary

Inhibikase Therapeutics beats Virpax Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Virpax Pharmaceuticals (NASDAQ:VRPX) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Virpax Pharmaceuticals and Viracta Therapeutics, as reported by MarketBeat.com.

Viracta Therapeutics has a consensus target price of $33.50, suggesting a potential upside of 308.04%. Given Viracta Therapeutics' higher probable upside, analysts plainly believe Viracta Therapeutics is more favorable than Virpax Pharmaceuticals.

Profitability

This table compares Virpax Pharmaceuticals and Viracta Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Virpax Pharmaceuticals and Viracta Therapeutics' top-line revenue, earnings per share and valuation.

Summary

Viracta Therapeutics beats Virpax Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Curative Biotechnology (NASDAQ:CUBT) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Curative Biotechnology and Virpax Pharmaceuticals, as reported by MarketBeat.

Valuation and Earnings

This table compares Curative Biotechnology and Virpax Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Curative Biotechnology and Virpax Pharmaceuticals' net margins, return on equity and return on assets.

Virpax Pharmaceuticals (NASDAQ:VRPX) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current ratings for Virpax Pharmaceuticals and NLS Pharmaceutics, as provided by MarketBeat.

NLS Pharmaceutics has a consensus price target of $10.6667, indicating a potential upside of 216.52%. Given NLS Pharmaceutics' higher probable upside, analysts clearly believe NLS Pharmaceutics is more favorable than Virpax Pharmaceuticals.

Valuation and Earnings

This table compares Virpax Pharmaceuticals and NLS Pharmaceutics' top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Virpax Pharmaceuticals and NLS Pharmaceutics' net margins, return on equity and return on assets.

Summary

NLS Pharmaceutics beats Virpax Pharmaceuticals on 2 of the 2 factors compared between the two stocks.